GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (NAS:TCBP) » Definitions » Total Liabilities

TC BioPharm (Holdings) (TC BioPharm (Holdings)) Total Liabilities : $7.86 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) Total Liabilities?

TC BioPharm (Holdings)'s Total Liabilities for the quarter that ended in Mar. 2024 was $7.86 Mil.

TC BioPharm (Holdings)'s quarterly Total Liabilities increased from Jun. 2023 ($7.86 Mil) to Dec. 2023 ($7.91 Mil) but then declined from Dec. 2023 ($7.91 Mil) to Mar. 2024 ($7.86 Mil).

TC BioPharm (Holdings)'s annual Total Liabilities declined from Dec. 2021 ($32.69 Mil) to Dec. 2022 ($13.35 Mil) and declined from Dec. 2022 ($13.35 Mil) to Dec. 2023 ($7.91 Mil).


TC BioPharm (Holdings) Total Liabilities Historical Data

The historical data trend for TC BioPharm (Holdings)'s Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) Total Liabilities Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
16.62 14.27 32.69 13.35 7.91

TC BioPharm (Holdings) Quarterly Data
Dec19 Sep20 Dec20 Jun21 Sep21 Dec21 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.35 - 7.86 7.91 7.86

TC BioPharm (Holdings) Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

TC BioPharm (Holdings)'s Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.014+(1.894+-0.0020000000000004
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=7.91

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=11.306-3.399
=7.91

TC BioPharm (Holdings)'s Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.053+(1.804+0.00099999999999967
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=7.86

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=9.23-1.372
=7.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TC BioPharm (Holdings) Total Liabilities Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


TC BioPharm (Holdings) (TC BioPharm (Holdings)) Business Description

Traded in Other Exchanges
Address
Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.
Executives
Renaissance Capital Partners Ltd 10 percent owner 42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD